ALK and cystic kidney disease: The results of the IRR conducted in 272 patients (255 treated with crizotinib and 17 with chemotherapy) from three clinical trials presented here represent the first large-scale systematic examination of the incidence of renal cysts in patients with ALK-positive NSCLC treated with crizotinib.